Headlands Technologies LLC Buys Shares of 9,368 Celcuity, Inc. $CELC

Headlands Technologies LLC purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 9,368 shares of the company’s stock, valued at approximately $980,000.

Several other institutional investors and hedge funds have also modified their holdings of CELC. EverSource Wealth Advisors LLC boosted its stake in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets raised its position in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the last quarter. Parallel Advisors LLC bought a new position in Celcuity in the 1st quarter valued at approximately $38,000. Finally, Meeder Asset Management Inc. bought a new position in shares of Celcuity during the fourth quarter valued at $42,000. 63.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Citigroup reissued a “market outperform” rating on shares of Celcuity in a research note on Monday, August 17th. Citizens Jmp restated a “market outperform” rating and issued a $177.00 price target on shares of Celcuity in a research report on Monday, August 17th. Leerink Partners set a $155.00 price objective on shares of Celcuity in a research report on Tuesday, June 2nd. Craig Hallum reissued a “buy” rating and set a $178.00 target price on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Guggenheim boosted their target price on shares of Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a report on Monday, August 17th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Price Performance

Celcuity stock opened at $91.98 on Wednesday. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of -21.39 and a beta of 0.21. Celcuity, Inc. has a 52-week low of $44.42 and a 52-week high of $151.02. The stock’s 50 day moving average price is $94.66 and its two-hundred day moving average price is $106.96. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, equities analysts predict that Celcuity, Inc. will post -4.75 earnings per share for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.